Erratum: De Bruyne E, Bos TJ, Schuit F, et al. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood. 2010;115(12):2430-2440. (Blood (2010) 115(12) (2430–2440), (S0006497120565944), (10.1182/blood-2009-07-232801));IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms

Blood

Volumn 115, Issue 12, 2010, Pages 2430-2440

  De Bruyne, Elke ^a   Bos, Tomas J ^a   Schuit, Frans ^b   Van Valckenborgh, Els ^a   Menu, Eline ^a   Thorrez, Lieven ^b   Atadja, Peter ^c   Jernberg Wiklund, Helena ^d   Vanderkerken, Karin ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BIM PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PANOBINOSTAT; PROTEIN KINASE B; SOMATOMEDIN C; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL CELL; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG POTENTIATION; EPIGENETICS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION;

EID: 77950556094     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood.2023022049     Document Type: Erratum

References (54)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336(23):1657-1664.
2. Yasui H, Hideshima T, Richardson PG, Anderson KC. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol. 2006;132(4):385-397. (Pubitemid 43381614)
3. Menu E, Van Valckenborgh E, Van Camp B, Vanderkerken K. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem. 2009;115(2):49-57.
4. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5(3):221-230.
5. Sprynski AC, Hose D, Caillot L, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009;113(19):4614-4626.
6. Menu E, Kooijman R, Van Valckenborgh E, et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer. 2004;90(5):1076-1083. (Pubitemid 38495831)
7. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood. 1999;93(1):235-241. (Pubitemid 29019408)
8. Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood. 2002;99(11):4138-4146. (Pubitemid 35332058)
9. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica. 2005;90(5):706-707. (Pubitemid 40780900)
10. Standal T, Borset M, Lenhoff S, et al. Serum insulin like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood. 2002;100(12):3925-3929. (Pubitemid 35396856)
11. Menu E, Jernberg-Wiklund H, Stromberg T, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood. 2006;107(8):655-660. (Pubitemid 43076391)
12. Stromberg T, Ekman S, Girnita L, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood. 2006;107(2):669-678. (Pubitemid 43076393)
13. Kuroda J, Taniwaki M. Involvement of BH3-only proteins in hematologic malignancies. Crit Rev Oncol Hematol. 2009;71(2):89-101.
14. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008;27(50):6398-6406.
15. Fennell DA, Chacko A, Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene. 2008;27(9):1189-1197. (Pubitemid 351294694)
16. O'Connor L, Strasser A, O'Reilly LA, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 1998;17(2):384-395. (Pubitemid 28045479)
17. Gomez-Bougie P, Bataille R, Amiot M. Endogenous association of Bim BH3-only protein with Mcl-1, Bcl-xL and Bcl-2 on mitochondria in human B cells. Eur J Immunol. 2005;35(3):971-976. (Pubitemid 40425553)
18. Gomez-Bougie P, Bataille R, Amiot M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol. 2004;34(11):3156-3164. (Pubitemid 39549394)
19. Hubner A, Barrett T, Flavell RA, Davis RJ. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell. 2008;30(4):415-425. (Pubitemid 351672377)
20. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the proapoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol. 2000;10(19):1201-1204.
21. Luciano F, Jacquel A, Colosetti P, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003;22(43):6785-6793. (Pubitemid 37372218)
22. Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia. 2005;7(7):646-657. (Pubitemid 41099418)
23. Fiskus W, Pranpat M, Bali P, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood. 2006;108(2):645-652. (Pubitemid 44061366)
24. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood. 2007;109(1):271-280. (Pubitemid 46053067)
25. Hazlehurst LA, Enkemann SA, Beam CA, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003;63(22):7900-7906.
26. Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196-206. (Pubitemid 36896125)
27. Vanderkerken K, Asosingh K, Willems A, et al. The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods Mol Med. 2005;113:191-205.
28. Karpas A, Fisher P, Swirsky D. Human plasmacytoma with an unusual karyotype growing in vitro and producing light-chain immunoglobulin. Lancet. 1982;1(8278):931-933. (Pubitemid 12146358)
29. Katagiri S, Yonezawa T, Kuyama J, et al. Two distinct human myeloma cell lines originating from one patient with myeloma. Int J Cancer. 1985;36(2):241-246. (Pubitemid 15243451)
30. Pegoraro L, Malavasi F, Bellone G, et al. The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. Blood. 1989;73(4):1020-1027. (Pubitemid 19078382)
31. Lombardi L, Poretti G, Mattioli M, et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer. 2007;46(3):226-238. (Pubitemid 46155318)
32. Pontén F, Gry M, Fagerberg L, et al. A global view of protein expression in human cells, tissues, and organs. Mol Syst Biol. 2009;5:337.
33. Essafi A, Fernandez de Mattos S, Hassen YA, et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene. 2005;24(14):2317-2329. (Pubitemid 40546691)
34. Reynolds A, Leake D, Boese Q, et al. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22(3):326-330. (Pubitemid 38295766)
35. Breckpot K, Dullaers M, Bonehill A, et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med. 2003;5(8):654-667. (Pubitemid 40309704)
36. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev. 2005;15(5):490-495.
37. Hazlehurst LA, Argilagos RF, Dalton WS. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br J Haematol. 2007;136(2):269-275.
38. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J. 2004;380(2):297-309. (Pubitemid 38788101)
39. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10(11):3839-3852. (Pubitemid 38697620)
40. Rahmani M, Anderson A, Habibi JR, et al. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood. 2009;114(20):4507-4516
41. Chen S, Dai Y, Pei XY, Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol. 2009;29(23):6149-6169.
42. Morales AA, Gutman D, Lee KP, Boise LH. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood. 2008;111(10):5152-5162.
43. Romagnoli M, Seveno C, Wuilleme-Toumi S, et al. The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma. Br J Haematol. 2009;145(2):180-189.
44. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 2006;20(1):1-13. (Pubitemid 43106714)
45. Margueron R, Trojer P, Reinberg D. The key to development: interpreting the histone code? Curr Opin Genet Dev. 2005;15(2):163-176. (Pubitemid 40416728)
46. Gilbert J, Gore SD, Herman JG, Carducci MA. The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res. 2004;10(14):4589-4596. (Pubitemid 38955507)
47. Chim CS, Kwong YL, Fung TK, Liang R. Methylation profiling in multiple myeloma. Leuk Res. 2004;28(4):379-385.
48. Pompeia C, Hodge DR, Plass C, et al. Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res. 2004;64(10):3465-3473. (Pubitemid 38657919)
49. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108(10):3441-3449.
50. Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006;66(11):5781-5789. (Pubitemid 43927132)
51. Kawamoto K, Hirata H, Kikuno N, et al. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer. 2008;123(3):535-542. (Pubitemid 351898410)
52. Essaghir A, Dif N, Marbehant CY, Coffer PJ, Demoulin JB. The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem. 2009;284(16):10334-10342
53. Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell. 2008;31(4):449-461.
54. Schulz WA, Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med. 2006;10(1):100-125. (Pubitemid 44874294)